93,420 Shares in Omeros Corporation $OMER Purchased by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. acquired a new stake in shares of Omeros Corporation (NASDAQ:OMER) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 93,420 shares of the biopharmaceutical company’s stock, valued at approximately $280,000.

A number of other institutional investors have also bought and sold shares of OMER. Deutsche Bank AG boosted its holdings in shares of Omeros by 4.9% during the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock worth $345,000 after purchasing an additional 1,973 shares during the last quarter. Harbour Investments Inc. lifted its position in Omeros by 46.1% during the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares in the last quarter. Cypress Capital Group boosted its stake in Omeros by 20.7% during the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 7,200 shares during the last quarter. Intech Investment Management LLC boosted its stake in Omeros by 28.4% during the second quarter. Intech Investment Management LLC now owns 34,108 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 7,538 shares during the last quarter. Finally, Bank of Montreal Can grew its holdings in Omeros by 1.4% in the 2nd quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company’s stock valued at $1,713,000 after buying an additional 8,000 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Stock Performance

Shares of OMER stock opened at $9.20 on Tuesday. The firm has a market cap of $652.28 million, a P/E ratio of -4.55 and a beta of 2.48. The firm’s 50 day moving average price is $8.14 and its 200-day moving average price is $5.35. Omeros Corporation has a one year low of $2.95 and a one year high of $13.60.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. As a group, research analysts predict that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OMER has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Saturday. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.67.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.